{
    "nctId": "NCT06318507",
    "briefTitle": "The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy",
    "officialTitle": "The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years\n* Female biological sex\n* Newly diagnosed, previously untreated, histologically confirmed early triple-negative breast cancer\n* Plan to initiate preoperative anti-PD-1 immunotherapy using pembrolizumab\n* Overweight or obesity, defined as a body mass index \\>=25 kg/m2\n* Ability to provide written informed consent\n* Allow the collection and storage of biospecimens and data for future use\n\nExclusion Criteria:\n\n* Active autoimmune disease\n* Concomitant conditions that require the use of antibiotics (e.g., chronic sinusitis)\n* Digestive disease disorders (e.g., irritable bowel syndrome, Crohn's disease)\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks\n* Recent (within 90 days) use of glucocorticoids for more than 10 consecutive days\n* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, or other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol\n* Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}